Document and Entity Information Document Information [Table] Document Information [Line Items] Document and Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Document Fiscal Period Focus Document Fiscal Year Focus Condensed consolidated statement of comprehensive income Revenue from sale of goods Product Sales The amount of alliance revenue Alliance Revenue The amount of revenue arising from the sale of goods and alliance revenue. Product revenue Product Revenue The amount of revenue arising from transactions involving the Company's medicines as well as medicine the Company has acquired an interest in. Such income included upfront consideration, milestones receipts and royalties, as well as other income from collaborations. Collaboration Revenue.. Collaboration Revenue Total collaboration revenue Revenue Total Revenue Cost of sales Cost of sales Gross profit Gross profit Distribution costs Distribution expense Research and development expense Research and development expense Selling, general and administrative expense Selling, general and administrative expense Other operating income (expense) Other operating income and expense Total other operating income and expense Profit (loss) from operating activities Operating profit Finance income Finance income Finance costs Finance expense Share of profit (loss) of associates and joint ventures accounted for using equity method Share of after tax losses in associates and joint ventures Profit (loss) before tax Profit before tax Profit before tax Tax expense (income) Taxation Profit (loss) Profit for the period Profit for the period Other comprehensive income [abstract] Other comprehensive income: Other comprehensive income, before tax, gains (losses) on remeasurements of defined benefit plans Remeasurement of the defined benefit pension liability Other comprehensive income, before tax, gains (losses) from investments in equity instruments Net gains/(losses) on equity investments measured at fair value through Other comprehensive income Income tax relating to components of other comprehensive income that will not be reclassified to profit or loss Tax expense on items that will not be reclassified to profit or loss Other comprehensive income that will not be reclassified to profit or loss, net of tax Total other comprehensive income that will not be reclassified to profit and loss, net of tax Other comprehensive income, before tax, exchange differences on translation of foreign operations Foreign exchange arising on consolidation The gains (losses) recognised in other comprehensive income on exchange difference hedges of net investments in foreign operations, before tax. Gains (losses) on exchange difference hedges of net investments in foreign operations, before tax Foreign exchange arising on designated liabilities in net investment hedges Gains (losses) on cash flow hedges, before tax Fair value movements on cash flow hedges Reclassification adjustments on cash flow hedges, before tax Fair value movements on cash flow hedges transferred to profit and loss Other comprehensive income, before tax, hedges of net investments in foreign operations Fair value movements on derivatives designated in net investment hedges The amount of gains (cost) of hedging. Gains (costs) of hedging before tax Gains of hedging Income tax relating to components of other comprehensive income that will be reclassified to profit or loss Tax income/(expense) on items that may be reclassified subsequently to profit and loss Other comprehensive income that will be reclassified to profit or loss, net of tax Total other comprehensive income that may be reclassified subsequently to profit and loss, net of tax Other comprehensive income Other comprehensive income, for the period, net of tax Other comprehensive income (expense) Comprehensive income Total comprehensive income for the period Profit (loss), attributable to [abstract] Profit/(loss) attributable to: Profit (loss), attributable to owners of parent Owners of the Parent Profit (loss), attributable to non-controlling interests Non-controlling interests Comprehensive income attributable to [abstract] Total comprehensive income attributable to: Comprehensive income, attributable to owners of parent Owners of the Parent Comprehensive income, attributable to non-controlling interests Non-controlling interests Earnings per share [abstract] Earnings per share Basic earnings (loss) per share Basic earnings per $0.25 Ordinary Share Diluted earnings (loss) per share Diluted earnings per $0.25 Ordinary Share Weighted average number of ordinary shares used in calculating basic earnings per share Weighted average number of Ordinary Shares in issue (millions) Weighted average number of ordinary shares used in calculating diluted earnings per share Diluted weighted average number of Ordinary Shares in issue (millions) Par value per share Par value per ordinary share Condensed consolidated statement of financial position Assets [abstract] Assets Non-current assets [abstract] Non-current assets Property, plant and equipment Property, plant and equipment Right-of-use assets Right-of-use assets Goodwill Goodwill Intangible assets other than goodwill Intangible assets Investments accounted for using equity method Investments in associates and joint ventures Non-current investments other than investments accounted for using equity method Other investments Non-current derivative financial assets Derivative financial instruments Other non-current receivables Other receivables Current tax assets, non-current Income tax receivable Deferred tax assets Deferred tax assets Non-current assets Total non-current assets Current assets [abstract] Current assets Current inventories Inventories Trade and other current receivables Trade and other receivables Current investments Other investments - current at end of period Other investments - current at beginning of period Other investments Current derivative financial assets Derivative financial instruments Intangible assets, classified as current Intangible assets, classified as current Intangible assets Current tax assets, current Income tax receivable Cash and cash equivalents Cash and cash equivalents at the end of the period Cash and cash equivalents at the beginning of the period Cash and cash equivalents Current assets Total current assets Assets Total assets Liabilities [abstract] Liabilities Current liabilities [abstract] Current liabilities Current borrowings and current portion of non-current borrowings Interest-bearing loans and borrowings Interest-bearing loans and borrowings at end of period Interest-bearing loans and borrowings at beginning of period Current lease liabilities Current instalments of leases at end of period Current instalments of leases at beginning of period Lease liabilities Trade and other current payables Trade and other payables Current derivative financial liabilities Derivative financial instruments Current provisions Provisions Current tax liabilities, current Income tax payable Current liabilities Total current liabilities Non-current liabilities [abstract] Non-current liabilities Non-current portion of non-current borrowings Interest-bearing loans and borrowings Non-current installments of loans at end of period Non-current installments of loans at beginning of period Non-current lease liabilities Non-current installments of leases at end of period Non-current installments of leases at beginning of period Lease liabilities Non-current derivative financial liabilities Derivative financial instruments Deferred tax liabilities Deferred tax liabilities Non-current net defined benefit liability Retirement benefit obligations Non-current provisions Provisions Current tax liabilities, non-current Income tax payable Trade and other non-current payables Other payables Non-current liabilities Total non-current liabilities Liabilities Total liabilities Assets (liabilities) Net assets Equity [abstract] Equity Issued capital Share capital Share premium Share premium account Other reserves Retained earnings Retained earnings Equity attributable to owners of parent Capital and reserves attributable to equity holders of the Parent Non-controlling interests Equity Equity at end of period Equity at beginning of period Total equity Condensed consolidated statement of changes in equity Statement of changes in equity [table] Components of equity [axis] Components of equity [domain] Equity attributable to owners of parent [member] Total attributable to owners of the parent Issued capital [member] Share capital Share premium [member] Share premium account Other reserves [member] Other reserves Retained earnings [member] Retained earnings Non-controlling interests [member] Non-controlling interests Statement of changes in equity [line items] Condensed consolidated statement of changes in equity The increase (decrease) in equity resulting from transfers between the other reserves and retained earnings. Increase (decrease) through transfer between other reserves and retained earnings, equity Transfer to Other reserves The amount of dividends, net of forfeitures, recognised as distributions to owners of the parent. Dividends recognised as distributions to owners of parent, net of forfeiture Dividends Issue of equity Issue of Ordinary Shares Increase (decrease) through changes in ownership interests in subsidiaries that do not result in loss of control, equity Changes in non-controlling interests Increase (decrease) through treasury share transactions, equity Movement in shares held by Employee Benefit Trusts Increase (decrease) through share-based payment transactions, equity Share-based payments charge for the period The increase (decrease) in equity resulting from settlement of share plan awards. Settlement of share plan awards, Equity Settlement of share plan awards Increase (decrease) in equity Net movement Condensed consolidated statement of cash flows Cash flows from (used in) operating activities [abstract] Cash flows from operating activities Adjustments for finance income (cost) Finance income and expense Adjustments for undistributed profits of investments accounted for using equity method Share of after tax losses of associates and joint ventures Adjustments for depreciation and amortisation expense and impairment loss (reversal of impairment loss) recognised in profit or loss Depreciation, amortisation and impairment The increase (decrease) in working capital and short-term provisions. Increase (decrease) in working capital and Short Term Provisions Movement in working capital and short-term provisions Adjustments for losses (gains) on disposal of intangible assets to reconcile profit (loss) to net cash flow from (used in) operating activities. Adjustments for losses (gains) on disposal of intangible asset Gains on disposal of intangible assets Adjustment of contingent consideration due to change in fair value. Contingent consideration, fair value movement Fair value movements on contingent consideration arising from business combinations Other adjustments for non-cash items Non-cash and other movements Cash flows from (used in) operations Cash generated from operations Interest paid, classified as operating activities Interest paid Income taxes paid (refund), classified as operating activities Tax paid Cash flows from (used in) operating activities Net cash inflow from operating activities Cash flows from (used in) investing activities [abstract] Cash flows from investing activities The amount of contingent consideration paid on account of business combinations. Contingent consideration payment, business combinations, classified as investing activities Payment of contingent consideration from business combinations Payment of contingent consideration from business combinations Purchase of property, plant and equipment, classified as investing activities Purchase of property, plant and equipment Proceeds from sales of property, plant and equipment, classified as investing activities Disposal of property, plant and equipment Purchase of intangible assets, classified as investing activities Purchase of intangible assets Proceeds from sales of intangible assets, classified as investing activities Disposal of intangible assets Purchase of other long-term assets, classified as investing activities Purchase of non-current asset investments Proceeds from sales of other long-term assets, classified as investing activities Disposal of non-current asset investments Other inflows (outflows) of cash, classified as investing activities Movement in short-term investments, fixed deposits and other investing instruments Purchase of interests in investments accounted for using equity method Payments to associates and joint ventures Interest received, classified as investing activities Interest received Cash flows from (used in) investing activities Net cash outflow from investing activities Net cash flows from (used in) operating and investing activities Cash flows from (used in) operating and investing activities Net cash inflow before financing activities Cash flows from (used in) financing activities [abstract] Cash flows from financing activities Proceeds from issuing shares Proceeds from issue of share capital Payments to acquire or redeem entity's shares Own shares purchased by Employee Benefit Trusts Payments from changes in ownership interests in subsidiaries that do not result in loss of control Payments to acquire non-controlling interests Proceeds from borrowings, classified as financing activities Issue of loans and borrowings Repayments of borrowings, classified as financing activities Repayment of loans and borrowings Repayment of loans and borrowings Dividends paid, classified as financing activities Dividends paid The cash inflow or outflow from hedge contracts relating to dividend payments (receipts). Hedge contracts relating to dividend payments (receipts) , classified as financing activities Hedge contracts relating to dividend payments Payments of lease liabilities, classified as financing activities Repayment of obligations under leases Cash flows from (used in) increase (decrease) in current borrowings Movement in short-term borrowings Cash flows from (used in) financing activities Net cash outflow from financing activities Increase (decrease) in cash and cash equivalents before effect of exchange rate changes Net (decrease)/increase in Cash and cash equivalents in the period Cash and cash equivalents if different from statement of financial position Cash and cash equivalents at the end of the period Cash and cash equivalents at the beginning of the period Total Cash and cash equivalents Effect of exchange rate changes on cash and cash equivalents Exchange rate effects Bank overdrafts Overdrafts na Basis of preparation and accounting policies The entire disclosure for the basis of presentation and significant accounting policies concepts. Ifrs Basis of Presentation and Significant Accounting Policies [Text Block] Basis of preparation and accounting policies Intangible assets Disclosure of intangible assets [text block] Intangible assets na Net debt. The entire disclosure of net debt. Disclosure of Net Debt [Text Block] Net debt Financial Instruments Disclosure of financial instruments [text block] Financial Instruments n/a Legal proceedings and contingent liabilities Disclosure of commitments and contingent liabilities [text block] Legal proceedings and contingent liabilities Product sales, year to date analysis Product Sales year-on-year analysis: H1 2026 Disclosure of revenue product sales, year to date analysis Disclosure of revenue product sales, year to date analysis [Text Block] Product Sales year-on-year analysis: H1 2026 n/a Product Sales year-on-year analysis: Q2 2026 The entire disclosure for product sales analysis, current period, year-on-year. Disclosure of Revenue Product Sales Analysis Current Period [Text Block] Product Sales year-on-year analysis: Q2 2026 Alliance revenue Alliance Revenue. The disclosure of alliance revenue Disclosure of alliance revenue [Text Block] Alliance Revenue Collaboration Revenue. Disclosure of collaboration revenue Disclosure of collaboration revenue [Text Block] Collaboration Revenue Other operating income and expense Disclosure of other operating income (expense) [text block] Other operating income and expense Disclosure of basis of preparation of financial statements [text block] Basis of preparation and accounting policies Disclosure of going concern [text block] Going concern Disclosure of accounting policy pertaining to legal proceedings. Legal Proceedings [Policy Text Block] Legal proceedings The tabular disclosure of net debt. Tabular Disclosure of Net Debt [Table Text Block] Schedule of Net debt The disclosure of the disaggregation of revenue from contracts with customers, current half year period, year-on-year. Disclosure Of Disaggregation Of Revenue From Contracts With Customers, Current Half Year Period, Year On Year [Table Text Block] Product Sales year-on-year analysis: H1 2026 The disclosure of the disaggregation of revenue from contracts with customers, current period, year-on-year. Disclosure Of Disaggregation Of Revenue From Contracts With Customers, Current Period, Year On Year [Table Text Block] Product Sales year-on-year analysis: Q2 2026 Tabular disclosure of alliance revenue Schedule of alliance revenue [Table Text Block] Schedule of alliance revenue Disclosure of disaggregation of revenue from contracts with customers [table] Disclosure of disaggregation of revenue from contracts with customers [line items] Revenues Product sales Disclosure of disaggregation of revenue from contracts with customers [text block] Schedule of collaboration revenue The disclosure of other operating income or expense. Disclosure of other operating income (expense) [table text block] Schedule of other operating income and expense Disclosure of detailed information about borrowings [table] Maturity [axis] Maturity [domain] Not later than one year [member] Due within one year Disclosure of detailed information about borrowings [line items] Basis of preparation and accounting policies Net debt na Going Concern [Abstract] Going concern The amount of financial resources that include cash, undrawn committed bank facilities less outstanding debt due within one year. Financial resources that include cash, undrawn committed bank facilities excluding current outstanding debt Financial resources Undrawn borrowing facilities Undrawn committed bank facilities Borrowings Gross borrowings at end of period Gross borrowings at beginning of period Disclosure of detailed information about intangible assets [table] Classes of intangible assets other than goodwill [axis] Classes of intangible assets other than goodwill [domain] Intangible assets under development [member] Products in development This member represents intangible assets from the collaboration and license agreement with CSPC Pharmaceuticals. Intangible assets from collaboration and license agreement with CSPC Pharmaceuticals [member] Intangible assets from collaboration and license agreement with CSPC Pharmaceuticals Disclosure of detailed information about intangible assets [line items] Intangible assets Impairment loss recognised in profit or loss, intangible assets other than goodwill Number of programmes initially progressed under collaboration agreement. Number of programmes initially progressed under collaboration agreement Additions other than through business combinations, intangible assets other than goodwill Maximum payables for regulatory milestones under collaboration agreement. Maximum payables for regulatory milestones under collaboration agreement Borrowings by name [axis] Borrowings by name [domain] Long-term borrowings [member] Long-term loans This member stands for commercial paper. Commercial paper This member stands for collateral received from derivative counterparties Collateral received from derivative counterparties [Member] Collateral received from derivative counterparties This member stands for other short-term borrowings excluding overdrafts. Other short-term borrowings excluding overdrafts This member stands for bank overdrafts. Overdrafts Increase (decrease) in non-current instalments of loans due to cash activity. Cash Flow, Non-Current Instalments of Loans Non-current instalments of loans - Cash flow Increase (decrease) in non-current borrowings due to non-cash and other movements. Non-cash and Other Movements, Non-current Borrowings Non-current installments of loans - Non-cash & other The increase (decrease) in non-current borrowings resulting from foreign exchange. Increase (decrease) through foreign exchange, Non-current Borrowings Non-current installments of loans - Exchange movements Increase (decrease) in non-current leases due to non-cash and other movements. Non-cash and Other Movements, Non-current Leases Non-current installments of leases - Non-cash & other The increase (decrease) in non-current leases resulting from foreign exchange. Effect of exchange rate changes on non-current Leases Non-current installments of leases - Exchange movements The amount of non-current borrowings which may include debt as well as lease liabilities. Noncurrent Borrowings Total long-term debt at end of period Total long-term debt at beginning of period Increase (decrease) in total non-current borrowings due to cash activity. Cash Flow, Total Non-current Borrowings Total long-term debt - Cash flow Increase (decrease) in total non-current borrowings due to non-cash and other movements. Non-cash and Other Movements, Total Non-current Borrowings Total long-term debt - Non-cash & other The increase (decrease) in total non-current borrowings resulting from foreign exchange. Effect of exchange rate changes on total Non-current Borrowings Total long-term debt - Exchange movements Current portion of non-current borrowings Current instalments of loans at end of period Current instalments of loans at beginning of period Increase (decrease) in current borrowings due to cash activity. Cash Flow Current Borrowings Current instalments of loans - Cash flow Increase (decrease) in current borrowings due to non-cash and other movements. Non-cash and Other Movements, current Borrowings Current instalments of loans - Non-cash & other The increase (decrease) in current borrowings resulting from foreign exchange. Effect of exchange rate changes on current instalments of loans Current instalments of loans - Exchange movements Increase (decrease) in current leases due to cash activity. Cash Flow, Current Leases Current instalments of leases - Cash flow Increase (decrease) in current leases due to non-cash and other movements. Non-cash and Other Movements, current Leases Current instalments of leases - Non-cash & other The increase (decrease) in current leases resulting from foreign exchange. Effect of exchange rate changes on current Leases Current instalments of leases - Exchange movements Increase (decrease) in Current borrowings and current portion of non-current borrowing due to cash activity. Cash Flow, Current borrowings and current portion of non-current borrowing Current borrowings and current portion of non-current borrowing - Cash flow The increase (decrease) in current borrowings and current portion of non-current borrowing resulting from foreign exchange. Effect of exchange rate changes on Current borrowings and current portion of non-current borrowing Current borrowings and current portion of non-current borrowing - Exchange movements The amount of current borrowings which may include debt as well as lease liabilities. Current Borrowings. Total current debt at end of period Total current debt at beginning of period Increase (decrease) in total current borrowings due to cash activity. Cash Flow, Total current Borrowings Total current debt - Cash flow Increase (decrease) in total current borrowings due to non-cash and other movements. Non-cash and Other Movements, Total current Borrowings Total current debt - Non-cash & other The increase (decrease) in total current borrowings resulting from foreign exchange. Effect of exchange rate changes on total current Borrowings Total current debt - Exchange movements Increase (decrease) in gross borrowings due to cash activity. Cash Flow, Gross Borrowings Gross borrowings - Cash flow Increase (decrease) in gross borrowings due to non-cash and other movements. Non-cash and Other Movements, Gross Borrowings Gross borrowings - Non-cash & other The increase (decrease) in gross borrowings resulting from foreign exchange. Effect of exchange rate changes on Gross Borrowings Gross borrowings - Exchange movements Net derivative financial instruments Net derivative financial instruments Net derivative financial instruments at end of period Net derivative financial instruments at beginning of period Increase (decrease) in net derivative financial instruments due to cash activity. Cash Flow, Net Derivative financial instruments Net derivative financial instruments - Cash flow Increase (decrease) in net derivative financial instruments due to non-cash and other movements. Non-cash and Other Movements, Net Derivative financial instruments Net derivative financial instruments - Non-cash & other The amount of total borrowings less net derivative financial instruments. Net Borrowings Net borrowings at end of period Net borrowings at beginning of period Increase (decrease) in net borrowings due to cash activity. Cash Flow, Net Borrowings Net borrowings - Cash flow Increase (decrease) in net borrowings due to non-cash and other movements. Non-cash and Other Movements, Net Borrowings Net borrowings - Non-cash & other The increase (decrease) in net borrowings resulting from foreign exchange. Effect of exchange rate changes on Net Borrowings Net borrowings - Exchange movements Increase (decrease) in cash and cash equivalents due to cash activity. Cash Flow, Cash and Cash Equivalents Cash and cash equivalents - Cash flow The increase (decrease) in cash and cash equivalents resulting from foreign exchange. Effect of exchange rate changes, Cash and Cash Equivalents Cash and cash equivalents - Exchange movements Increase (decrease) in other investments, current due to cash activity. Cash Flow, Other Investments, Current Other investments, current - Cash flow The total of cash and cash equivalents along with other investments. Cash and Cash Equivalents, Other Investments Cash and investments at end of period Cash and investments at beginning of period Increase (decrease) in cash and investments due to cash activity. Cash Flow, Cash and Investments Cash and investments - Cash flow The increase (decrease) in cash and investments resulting from foreign exchange. Effect of exchange rate changes On Cash and Investments Cash and investments - Exchange movements Net debt Net debt at end of period Net debt at beginning of period Increase (decrease) in net funds and borrowings due to cash activity. Cash Flow, Net Funds and Borrowings Net debt - Cash flow Increase (decrease) in net funds and borrowings due to non-cash and other movements. Non-cash and Other Movements, Net Funds and Borrowings Net debt - Non-cash & other The increase (decrease) in net funds and borrowings resulting from foreign exchange. Effect of exchange rate changes on Net Funds and Borrowings Net debt - Exchange movements The amount of increase (decrease) in the net debt position. Increase Decrease in Net Debt Position Increase (decrease) in net debt The amount of cash collateral on financial derivatives. Cash Collateral on Derivatives Cash collateral on financial derivatives The amount of cash collateral on financial derivatives by the group. Cash Collateral On Derivatives Posted by Group Cash collateral posted by the Group Disclosure of detailed information about business combination [table] Levels of fair value hierarchy [axis] Levels of fair value hierarchy [domain] Level 3 of fair value hierarchy [member] Level 3 Classes of financial assets [axis] Classes of financial assets [domain] Equity investments [member] Equity investments This member stands for other financial asset investments. Other Investments This member stands for money market funds. Money market funds Money market funds Derivatives [member] Derivatives Categories of financial assets [axis] Categories of financial assets [domain] This member represents financial assets measured at fair value Financial assets measured at fair value [Member] Financial assets measured at fair value Financial assets at amortised cost, category [member] Financial assets at amortised cost Classes of financial liabilities [axis] Classes of financial liabilities [domain] This member stands for interest-bearing loans and borrowings. Interest-Bearing Loans and Borrowings Interest-Bearing Loans and Borrowings Business combinations [axis] Business combinations [domain] This member stands for the Diabetes Alliance. Diabetes alliance Diabetes alliance Measurement [axis] Measurement [domain] Not measured at fair value in statement of financial position but for which fair value is disclosed [member] Not measured at fair value in statement of financial position but for which fair value is disclosed Disclosure of detailed information about business combination [line items] Disclosure of detailed information about business combination Financial assets designated as measured at fair value through profit or loss [abstract] Financial instruments fair value gains Financial assets Financial assets pledged as collateral for liabilities or contingent liabilities Cash collateral pledged to counterparties Financial liabilities Carrying value, financial liabilities Financial liabilities, at fair value Disclosure of contingent liabilities [table] Classes of contingent liabilities [axis] Classes of contingent liabilities [domain] This member represents the Forxiga patent proceedings in Europe. Forxiga patent proceedings, Europe [member] Forxiga patent proceedings, Europe This member stands for Tagrisso US patent proceedings. Tagrisso US patent proceedings [Member] Tagrisso US patent proceedings This member stands for the Definiens commercial litigation Definiens commercial litigation [Member] Definiens commercial litigation This member represents the Syntimmune Milestone Litigation in the US. Syntimmune Milestone Litigation, US [Member] Syntimmune Milestone Litigation, US This member stands for University Of Sheffield Contract Dispute, UK. University Of Sheffield Contract Dispute, UK [Member] University of Sheffield Contract Dispute, UK This member stands for Enhertu patent proceedings Enhertu patent proceedings [Member] Enhertu patent proceedings The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table. Classes of contingent assets [Axis] Contingent assets Contingent assets [Domain] This member represents the Forxiga patent proceedings in Australia. Forxiga patent proceedings, Australia [member] Forxiga patent proceedings, Australia This member stands for the Tagrisso Patent Proceedings in Russia. Tagrisso Patent Proceedings, Russia [Member] Tagrisso Patent Proceedings, Russia This member stands for the PARP Inhibitor Royalty Dispute. PARP Inhibitor Royalty Dispute Geographical areas [axis] Geographical areas [domain] FRANCE PORTUGAL POLAND Non-adjusting events after reporting period [axis] Non-adjusting events after reporting period [domain] This member stands for trial related to Forxiga patent proceedings. Trial For Forxiga Patent Proceedings [Member] Trial for forxiga patent proceedings Counterparties [axis] Counterparties [domain] This member represents the Russian Ministry of Health (MOH). Russian Ministry of Health (MOH) [Member] Russian Ministry of Health (MOH) Disclosure of contingent liabilities [line items] Number of patents being challenged. Number of patents being challenged Number of patents being challenged Number of patent trials concluded. Number Of Patent Trials Concluded Number of patent trials concluded Number of patents invalidated. Number of Patents Invalidated Number of patents invalidated Number of royalty-bearing patent license agreements. Number of Royalty Bearing Patent License Agreements Number of royalty-bearing patent license agreements Damages awarded, value. Damages awarded, value Damages awarded, Value Damages received from counterparty. Damages received from counterparty Number of patents claimed to be infringed. Number of patents claimed to be infringed Number of appeals prior to dismissal. Number of appeals prior to dismissal Represents the amount of the claim filed. Amount Of Claim Amount of claim Court decision on amount of milestone that had been reached. Court decision on amount of milestone that had been reached Court decision on amount of milestone that had been reached Amount of consideration paid, payable, or recognized to settle litigation or other legal disputes.. Litigation Settlement Amount Litigation settlement amount Percentage of royalties on sales to pay to counterparty Percentage of royalties on sales to pay to counterparty Percentage of royalties on sales to pay to counterparty Number of proceedings in which counterparty has disclaimed all patents Number of proceedings in which counterparty has disclaimed all patents Number of proceedings in which counterparty has disclaimed all patents Products and services [axis] Products and services [domain] This member stands for oncology products. Total Oncology Total Oncology This member stands for Tagrisso. Tagrisso Tagrisso This member stands for Imfinzi. Imfinzi Imfinzi This member stands for Calquence. Calquence Calquence This member stands for Lynparza. Lynparza Lynparza This member stands for Enhertu. Enhertu Enhertu This member stands for Zoladex. Zoladex Zoladex This member stands for Truqap Truqap [Member] Truqap This member stands for Imjudo Imjudo [Member] Imjudo This member represents Datroway. Datroway [Member] Datroway This member stands for Etcamah. Etcamah [Member] Etcamah This member stands for other oncology products. Oncology, Others Other Oncology This member stands for cardiovascular, renal and metabolism products. BioPharmaceuticals: total CVRM BioPharmaceuticals: total CVRM This member stands for Farxiga. Farxiga Farxiga This member stands for Crestor. Crestor Crestor This member stands for Brilinta. Brilinta Brilinta This member stands for Lokelma. Lokelma Lokelma This member stands for Seloken. Seloken [Member] Seloken This member stands for Roxadustat. roxadustat roxadustat This member stands for Wainua Wainua [Member] Wainua This member stands for Baxfendy. Baxfendy [Member] Baxfendy This member stands for other cardiovascular, renal and metabolism products. CVRM, Others Other CVRM This member stands for respiratory and immunology products. BioPharmaceuticals: total Respiratory & Immunology BioPharmaceuticals: total Respiratory & Immunology This member stands for Symbicort. Symbicort Symbicort This member stands for Fasenra. Fasenra Fasenra This member stands for Breztri. Breztri Breztri This member stands for Tezspire. Tezspire Tezspire Saphnelo Saphnelo Saphnelo This member stands for Pulmicort. Pulmicort Pulmicort This member stands for Airsupra Airsupra [Member] Airsupra This member stands for other respiratory and immunology products. Respiratory, Others Other R&I This member stands for vaccine and infection. BioPharmaceuticals: Total V&I BioPharmaceuticals: Total V&I This member stands for Beyfortus Beyfortus [Member] Beyfortus This member stands for FluMist. FluMist FluMist Rare diseases Total rare diseases Total rare diseases Ultomiris Ultomiris Ultomiris Soliris Soliris Soliris Strensiq Strensiq Strensiq This member stands for Koselugo. Koselugo Koselugo This member represents Rare Disease, other. Rare Disease, other [Member] Other Rare Disease This member stands for other products. Total Other medicines Total Other medicines Markets of customers [axis] Markets of customers [domain] UNITED STATES US This member stands for the information pertaining to Emerging Markets. Emerging Markets Emerging Markets Europe [Member] Europe The member stands for established ROW. Established ROW Established RoW Revenue from sale of goods net of reversals Revenue from sale of goods net of reversals Product sales net of reversals Represents the actual increase (decrease) in revenue, year-on-year, as a percent. Increase (Decrease) In Revenue, Year On Year, Percentage Actual %, year-on-year Represents the increase (decrease) in revenue based on constant exchange rate, year-on-year, as a percent. Increase (Decrease) in Revenue, Constant Exchange Rate, Year On Year, as a Percentage CER %, year-on-year This member represents Infectious Disease. Infectious Disease [Member] ID This member represents Infectious Disease, other. Infectious Disease, other [member] Other ID Disclosure of products and services [table] This member represents other royalty income not separately disclosed in the same statement or note. Other royalty income [Member] Other royalty income This member stands for other alliance revenue Other alliance revenue [Member] Other Alliance Revenue Disclosure of products and services [line items] This member stands for Farxiga, sales milestones Farxiga, sales milestones [Member] Farxiga: sales milestones This member stands for Crestor, sales milestones. Crestor, sales milestones [Member] Crestor: sales milestones This member stands for other collaboration revenue. Other Collaboration Revenue Other Collaboration Revenue